March 2016 Volume 12, Issue 3
Volume 12, Issue 3 | March 2016
March 2016
In this Issue
Q&A
Q&A: Charles River Laboratories helps navigate the waters of immunotherapy
DDNews speaks with Bill Barbo, senior vice president of global sales and marketing for Charles River Laboratories, about such things as his company’s acquisition of WIL Research and the role Charles River is playing in advancing immunotherapy researchBusiness & Government Policy
Patent Docs: What’s in a name? When the chemical structure of an API is wrong
Drug regulation and licensing (and the patents that claim active pharmaceutical ingredients) are based on accuracy, including accurate descriptions of the molecule, how it is formulated and (to the extent it is understood) how it works. But what happens when there is an error?An early acquisition with Affymetrix
Thermo Fisher Scientific looks to acquire Affymetrix, with expected deal completion in Q2Biogen kicks off ALS funding challenge
With an initial $5-million donation, goal for Biogen and Target ALS is $20 million more in corporate fundingSealing the deals
Astellas, Bristol-Myers Squibb and Cipla all complete important deals in mid- to late-FebruaryOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsFor your approval
A collection of recent regulatory approvals and actions globallyCommentary
Out of order: Clinicians must return to basics
Medical journals aren't featuring as many basic science articles as they once did, and we should all be worried about that and what it bodes for precision medicine efforts and perhaps drug discovery and development more generally, too.Guest Commentary: Go parallel in a big way
Production of biotherapeutics can be improved significantly through the use of massively parallel combinatorial screeningEditor's Focus
A cancer cavalcade for March
The annual meeting of the AACR is coming up fast, and that has cancer on our minds and those of a lot of other people, especially drug discovery and development folks. Find out what’s in store for the March issue on the cancer front and some of the activities surrounding oncology right now.Feature
AACR 2016 Show Preview: The long and winding road
Key areas to be addressed at AACR annual meeting include immunotherapy, epigenetics and newer techniques and tools such as CRISPRClinical Trials
Getting the body to do the work
Immune Design shares positive top-line data from trio of Phase 1 trials in immuno- oncologyMore than ‘skin-deep’ success
Corium posts top-line interim results of transdermal Alzheimer’s patch for once- weekly dosingArchexin triggers dose-dependent tumor reduction in RCC
Rexahn progresses its Phase 2a clinical research in metastatic renal cell carcinomaNew hope with NEOD001?
AL amyloidosis candidate generates favorable cardiac and renal response in Phase 1/2Research & Development
Not just basic; translational, too
MedImmune and UCSF enter research collaboration aimed at respiratory conditions, inflammation and autoimmunityFinding a better human liver cell
Samsara-UC San Diego collaboration to focus on isolating and characterizing specialized human liver cellsA matter of models
Envigo shares findings on the effectiveness of its rat models in examining susceptibility and attenuation to HSV-2 infectionStriking a ‘G’ note on schizophrenia
Germany’s Boehringer Ingelheim and California’s Arena Pharmaceuticals collaborate in GPCR dealJohns Hopkins and MedImmune to train Ph.D. students for careers in biopharma
The Johns Hopkins University and MedImmune, have announced a first-of-its-kind Ph.D. training program between a major university and a biopharmaceutical company in the United StatesDiagnostics
Taking point in point-of-care
Abbott to acquire Alere for $5.8 billion and create point-of-care testing leaderAll about APOBEC3G
A gap caused during DNA replication could result in cancer-causing mutations‘One world, one health’
Minimally invasive method of testing for pathogens could provide new paradigm for characterizing disease transmissionA new biomarker for colon cancer
CDX2 identifies colon cancer patients who may benefit from chemotherapyDiscovery
Illumina signs biobank deals with four institutions
Prominent role of arrays in company’s overall portfolio recently has focused it more on biobank segmentEnzymes, ion channels and cryo-electron microscopy, oh my!
Recent advances in cryo- electron microscopy are enabling new discoveries at TSRITSRI researchers develop versatile new way to build molecules
Chemists at The Scripps Research Institute (TSRI) have devised a new, widely applicable technique for building potential drug moleculesFlying high in the cloud
Cloud Pharmaceuticals discovers how to design molecules faster and betterPreclinical
RedHill and Fraunhofer collaborate on cancer drug
Novel mechanism may be especially promising for pancreatic cancer patients
Gates Foundation bets big on Moderna’s mRNA technology
Grant will provide support for GLP toxicology studies, preparations for clinical trials and a Phase 1 studyCornering C. diff.
Immuron posts positive preclinical results for oral therapeutic IMM-529A novel approach to depression?
Rapastinel may sidestep cognitive deficits seen with ketamineContract Services
U.K.-based Onyx expands following strong year
Second such expansion since last year driven in part by demand for API servicesCOMPASS points east to Japan
EPS Corporation to run clinical studies using BioClinica RBM solutionBringing contract manufacturing closer
Novasep adds specialized drug development technologies for North American customersRadiant Sage expands service offering in Europe
Radiant Sage expands service offering in EuropeTraceLink boosts leadership position
Track-and-trace network exceeds 200,000 supply chain members
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Enhancing bioanalytical studies with centralized data management
Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Explained: How are metabolite biomarkers improving drug discovery and development?
By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Supercharging cell line development and engineering with automated single cell sorting
Researchers can enhance efficiency, yield, and consistency in clonal cell line development with specialized tools.
